Sequenta, Inc., a South San Francisco, CA-based biotechnology company developing clinical diagnostics based on immune cell receptor genes, received an equity investment from Celgene Corporation and other strategic investors.
This financing, in addition to funding secured from several other strategic investors, will support incorporation of the ClonoSIGHT™ minimal residual disease (MRD) test into clinical trials of medicines in development for various hematological malignancies (blood cancers) and development of new clinical diagnostics based on Sequenta’s LymphoSIGHT™ platform.
Founded in 2008 and led by Tom Willis, CEO, the company has developed the ClonoSIGHT™ Process which enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as a clinical decision-making tool for patients with lymphoid cancers (blood cancers).
Sequenta is also backed by Mohr Davidow Ventures, Index Ventures and Foresite Capital.
FinSMEs
20/10/2014